Start Time: 08:00 End Time: 08:52 Abiomed , Inc. (NASDAQ: ABMD ) Q1 2015 Earnings Conference Call July 31, 2014 ..... Good day, ladies and gentlemen. Welcome to the Abiomed , Inc. Q1 2015 Earnings Conference Call. At this
Abiomed ( ABMD -4.5% ) fiscal Q1 results : Total Revenues: $48.8M (+14.3%); Operating Expenses: $50.3M (+14.3%); Operating
QUIK -22% . DDD -13% . MTW -10% . VJET -10% . GLUU -9% . CODE -9% . ALU -9% . TTEK -9% . AKAM -7% . CTRP -7% . YUM -7% . LIQD -6% . OCN -6% . YPF -6% . WFM -6% . ABMD -6% . YELP -6% . VRX -5% . 1 comment!
Abiomed (NASDAQ: ABMD ): FQ1 EPS of -$0.04 may not be comparable to consensus of $0.02. Revenue of $48.8M (+14.4% Y/Y) misses by $0.82M . Press Release Post your comment!
AAWW , ABMD , ACIW , ACOR , ADP , AGI , ALKS , ALU , AMRC , APA , ASEI , ATK , AVP , AYR , AZN , BDX , BG , BGCP , BKCC , BLL , BUD , BWA
Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals
We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there
Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the
unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .